News | November 05, 2024
Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated
